QQQ   431.88 (+0.19%)
AAPL   169.45 (-1.88%)
MSFT   416.65 (+0.73%)
META   503.35 (+0.62%)
GOOGL   154.80 (-0.04%)
AMZN   184.20 (+0.32%)
TSLA   157.26 (-2.61%)
NVDA   871.13 (+1.29%)
AMD   163.01 (+1.68%)
NIO   3.82 (-1.80%)
BABA   69.64 (-1.39%)
T   16.06 (-1.11%)
F   12.14 (-0.74%)
MU   120.98 (-0.32%)
GE   155.43 (+1.13%)
CGC   7.03 (+0.72%)
DIS   114.24 (+1.14%)
AMC   2.73 (+10.53%)
PFE   25.85 (-0.23%)
PYPL   64.09 (+0.91%)
XOM   118.78 (-0.75%)
QQQ   431.88 (+0.19%)
AAPL   169.45 (-1.88%)
MSFT   416.65 (+0.73%)
META   503.35 (+0.62%)
GOOGL   154.80 (-0.04%)
AMZN   184.20 (+0.32%)
TSLA   157.26 (-2.61%)
NVDA   871.13 (+1.29%)
AMD   163.01 (+1.68%)
NIO   3.82 (-1.80%)
BABA   69.64 (-1.39%)
T   16.06 (-1.11%)
F   12.14 (-0.74%)
MU   120.98 (-0.32%)
GE   155.43 (+1.13%)
CGC   7.03 (+0.72%)
DIS   114.24 (+1.14%)
AMC   2.73 (+10.53%)
PFE   25.85 (-0.23%)
PYPL   64.09 (+0.91%)
XOM   118.78 (-0.75%)
QQQ   431.88 (+0.19%)
AAPL   169.45 (-1.88%)
MSFT   416.65 (+0.73%)
META   503.35 (+0.62%)
GOOGL   154.80 (-0.04%)
AMZN   184.20 (+0.32%)
TSLA   157.26 (-2.61%)
NVDA   871.13 (+1.29%)
AMD   163.01 (+1.68%)
NIO   3.82 (-1.80%)
BABA   69.64 (-1.39%)
T   16.06 (-1.11%)
F   12.14 (-0.74%)
MU   120.98 (-0.32%)
GE   155.43 (+1.13%)
CGC   7.03 (+0.72%)
DIS   114.24 (+1.14%)
AMC   2.73 (+10.53%)
PFE   25.85 (-0.23%)
PYPL   64.09 (+0.91%)
XOM   118.78 (-0.75%)
QQQ   431.88 (+0.19%)
AAPL   169.45 (-1.88%)
MSFT   416.65 (+0.73%)
META   503.35 (+0.62%)
GOOGL   154.80 (-0.04%)
AMZN   184.20 (+0.32%)
TSLA   157.26 (-2.61%)
NVDA   871.13 (+1.29%)
AMD   163.01 (+1.68%)
NIO   3.82 (-1.80%)
BABA   69.64 (-1.39%)
T   16.06 (-1.11%)
F   12.14 (-0.74%)
MU   120.98 (-0.32%)
GE   155.43 (+1.13%)
CGC   7.03 (+0.72%)
DIS   114.24 (+1.14%)
AMC   2.73 (+10.53%)
PFE   25.85 (-0.23%)
PYPL   64.09 (+0.91%)
XOM   118.78 (-0.75%)
NYSE:ENZ

Enzo Biochem (ENZ) Stock Price, News & Analysis

$1.16
0.00 (0.00%)
(As of 12:15 PM ET)
Today's Range
$1.15
$1.17
50-Day Range
$1.16
$1.39
52-Week Range
$1.15
$2.74
Volume
29,978 shs
Average Volume
93,878 shs
Market Capitalization
$59.43 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ENZ stock logo

About Enzo Biochem Stock (NYSE:ENZ)

Enzo Biochem, Inc. develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. It also provides AMPIVIEW in situ hybridization probes for enhanced detection of low expressed targets useful in the growing spatial biology space; reagents and assays for cell and gene therapy research and development; POLYVIEW PLUS Enhanced Immunohistochemistry platform, offers solutions within the area of anatomical pathology through optimized assays; Enhanced Immunoassays, pushing sensitivity to expand immunoassay applications for basic research, bioprocess, and diagnostics; AMPIPROBE, a nucleic acid amplification platform; and Axxora.com, a proven distribution platform for original manufacturers of innovative research reagents. The company's proprietary products and technologies in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry. It markets its products and services through its direct sales force and a network of distributors. The company was incorporated in 1976 and is headquartered in Farmingdale, New York.

ENZ Stock Price History

ENZ Stock News Headlines

Analyzing Enzo Biochem (NYSE:ENZ) and Fortrea (NASDAQ:FTRE)
Can't believe it's happening again
One of the single most unique and powerful events in the markets is coming in the next two months. It’s scheduled for April 22, 2024. But investors are moving now to get ahead of what’s coming… driving up prices of one asset dramatically. And you should do the same.
Enzo Biochem: Fiscal Q2 Earnings Snapshot
Enzo Biochem, Inc.
Can't believe it's happening again
One of the single most unique and powerful events in the markets is coming in the next two months. It’s scheduled for April 22, 2024. But investors are moving now to get ahead of what’s coming… driving up prices of one asset dramatically. And you should do the same.
Jim Simons Trims Stake in Enzo Biochem Inc
Enzo Biochem Appoints New CEO and CFO
Enzo Biochem Inc (EZB.SG)
Enzo Biochem Inc ENZ
See More Headlines
Receive ENZ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enzo Biochem and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
10/15/2019
Today
4/16/2024
Next Earnings (Estimated)
6/12/2024
Fiscal Year End
7/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medical laboratories
Sub-Industry
N/A
Employees
179
Year Founded
1976

Profitability

Net Income
$20.29 million
Pretax Margin
-71.07%

Debt

Sales & Book Value

Annual Sales
$31.06 million
Book Value
$1.58 per share

Miscellaneous

Free Float
43,286,000
Market Cap
$59.43 million
Optionable
Optionable
Beta
0.75

Social Links

These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

ENZ Stock Analysis - Frequently Asked Questions

How have ENZ shares performed in 2024?

Enzo Biochem's stock was trading at $1.39 at the beginning of the year. Since then, ENZ stock has decreased by 16.5% and is now trading at $1.16.
View the best growth stocks for 2024 here
.

Are investors shorting Enzo Biochem?

Enzo Biochem saw a decline in short interest during the month of February. As of February 29th, there was short interest totaling 715,400 shares, a decline of 9.8% from the February 14th total of 792,900 shares. Based on an average daily volume of 113,500 shares, the short-interest ratio is presently 6.3 days. Approximately 2.1% of the shares of the stock are short sold.
View Enzo Biochem's Short Interest
.

When is Enzo Biochem's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, June 12th 2024.
View our ENZ earnings forecast
.

How were Enzo Biochem's earnings last quarter?

Enzo Biochem, Inc. (NYSE:ENZ) released its quarterly earnings results on Tuesday, October, 15th. The medical research company reported ($0.11) EPS for the quarter, beating analysts' consensus estimates of ($0.14) by $0.03. The medical research company earned $20.92 million during the quarter. Enzo Biochem had a net margin of 99.28% and a negative trailing twelve-month return on equity of 36.71%.

What other stocks do shareholders of Enzo Biochem own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Enzo Biochem investors own include OneLife Technologies (OLMM), Gilead Sciences (GILD), OPKO Health (OPK), Teva Pharmaceutical Industries (TEVA), Inovio Pharmaceuticals (INO), AbbVie (ABBV), Pfizer (PFE), Advanced Micro Devices (AMD), Amarin (AMRN) and Micron Technology (MU).

How do I buy shares of Enzo Biochem?

Shares of ENZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:ENZ) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners